Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.78 USD

73.78
5,148,046

-0.56 (-0.75%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Stock Reports for Anheuser-Busch, Gilead & Canadian National

Today's Research Daily features new research reports on 16 major stocks, including Anheuser-Busch InBev (BUD), Gilead Sciences (GILD) and Canadian National Railway (CNI).

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $64.21, marking a -1.29% move from the previous day.

Sweta Killa headshot

Healthcare ETFs, Stocks That Gained Double Digits Last Week

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Ritujay Ghosh headshot

Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch

Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.

Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies

Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.

Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study

Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.

Roche's Actemra Meets Goal in Phase III Coronavirus Study

Roche's (RHHBY) phase III study, EMPACTA, evaluating Actemra in patients with COVID-19-associated pneumonia, meets primary endpoint.

Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day

Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day

Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

Lilly's Coronavirus Antibody Shows Positive Effect in Phase II

Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate.

Gilead's Oncology Drug Gets Breakthrough Therapy Designation

Gilead's (GILD) magrolimab obtains Breakthrough Therapy designation in the United States for the treatment of newly-diagnosed myelodysplastic syndrome (MDS).

Sweta Killa headshot

M&A ETFs Sizzling on Recent Deal Activities

After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.

Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $66.20, moving -0.21% from the previous trading session.

Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study

Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.

Sweta Killa headshot

Biotech ETFs Soars on Gilead-Immunomedics Deal

The acquisition will expand Gilead's portfolio of treatments for various types of cancer.

Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug

Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America

Stock Market News for Sep 15, 2020

U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

Sweta Killa headshot

ETFs in Focus on Tug of War Between Bulls and Bears

Both bull and bear ETFs are showing immense potential as abrupt changes in sentiments have raised the appeal for these products.

M&A Activities Intensify in Pharma Industry

M&A Activities Intensify in Pharma Industry.

Mark Vickery headshot

No Econ Data, but Big Biopharma News

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Gilead to Buy Oncology Company Immunomedics for $21 Billion

Gilead (GILD) looks to fortify its oncology portfolio with the acquisition of Immunomedics and the addition of Trodelvy to its portfolio.

Immunomedics to be Acquired by Gilead for About 21 Billion

Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed at $64.51 in the latest trading session, marking a +0.58% move from the prior day.

Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.